Lead candidate BM-3103 (TolaSure® Gel™) now holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations as BioMendics advances the TAMES-02 Phase 2 study (NCT07027345). AKRON, ...
BM-3103 is a first-in-class topical mTOR inhibitor that promotes autophagy to clear mutant keratin aggregates in epidermolysis bullosa simplex. The Food and Drug Administration (FDA) has granted Fast ...
AKRON, Ohio, June 23, 2026--(BUSINESS WIRE)--BioMendics, LLC, a clinical-stage biotechnology company developing innovative therapies for rare genetic skin disorders, today announced that the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results